PANCREATIC NEUROENDOCRINE TUMORS DECEMBER 12, 2017 IF YOU EXPERIENCE TECHNICAL DIFFICULTY DURING THE PRESENTATION:
|
|
- Blake Johnston
- 5 years ago
- Views:
Transcription
1 PANCREATIC NEUROENDOCRINE TUMORS DECEMBER 12, 2017 IF YOU EXPERIENCE TECHNICAL DIFFICULTY DURING THE PRESENTATION: CONTACT WEBEX TECHNICAL SUPPORT DIRECTLY AT: US TOLL FREE: TOLL ONLY: OR SUBMIT A QUESTION TO THE EVENT PRODUCER VIA THE Q&A PANEL Pancreatic Neuroendocrine Tumors Daniel M. Halperin, MD Assistant Professor Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center 1
2 Disclosures Consultant for Novartis, AbbVie. Research funded by Ipsen, Genentech, Novartis, Tarveda, Dicerna (prior). I will discuss off-label and/or investigational use. Disclosures (cont.) No webinar is a substitute for a personal consultation with a trusted physician. 2
3 Overview Basics of the pancreas and pancreatic neuroendocrine neoplasms (NENs) Epidemiology Clinical presentations Basic biology Modern treatment approaches Future investigational directions This is not conventional pancreas cancer 3
4 Pancreas Anatomy/Physiology 101 Exocrine Acinar cells produce digestive enzymes, delivered to the GI tract by ducts. Endocrine Islet cells secrete hormones into blood. Bardeesy and DePinho, Nat Rev Cancer Dec;2(12): Rising Incidence of Pancreatic NETs Pancreatic Adenocarcinoma 12.5/100,000 Dasari et al., JAMA Oncol Oct 1;3(10):
5 Rising Prevalence of Pancreatic NETs Dasari et al., JAMA Oncol Oct 1;3(10): NET Framework NETs arise from endocrine cells distributed throughout the aerodigestive tract, including the pancreas. Classified in four dimensions: Primary Site Grade Stage Functional Status (hormonal secretion) Histology of adenocarcinoma Hruban and Fukushima, Modern Pathology (2007) 20, S61 S70. Frequently express somatostatin receptors Histology of NET. A: H&E; B: CgA Halperin and Yao, MD Anderson Manual of Medical Oncology, 3e. 5
6 Grading NENs (2017) Grade 1 NET < 2 mitoses/10 HPF, Ki-67 <3% 2 NET 2-20 mitoses/10 HPF, Ki % 3 NET Well-differentiated >20 mitoses/10 HPF, Ki-67 >20% 3 NEC Poorly-differentiated >20 mitoses/10 HPF, Ki-67 >20% Grade is dependent on appearance and rate of cellular division Grade, Stage, Primary Site Grade 1-2 Grade 3 Metastatic Grade 1-2 NET Primary Tumor Site Appendix NA Cecum 98 Colon 14 Lung 24 Pancreas 60 Rectum 33 Small Intestine 103 Stomach 29 Median Survival (months) Yao et al., J Clin Oncol 2008; 26:3063 Dasari et al., JAMA Oncol Oct 1;3(10):
7 Functional Status Gastrinoma (gastrin) Glucagonoma (glucagon) Insulinoma (insulin) VIPoma (vasoactive intestinal peptide) Reflux Diabetes Low blood sugar Dementia Confusion Ulcers Dermatitis Improvement with eating Diarrhea Diarrhea DVT Weight gain Adapted with permission from James Yao Non-functional Presentations Completely incidental Symptoms from primary tumor Painless jaundice from pancreatic head tumor obstructing biliary drainage Bleeding gastric varices from pancreatic tail tumor occluding splenic vein Symptoms from metastatic disease Right upper quadrant pain from liver metastases 7
8 Genetics/Genomics Most pancreatic NETs are not inherited or associated with a familial syndrome MEN1 DAXX/ATRX TSC2, NF1 VHL BRCA2 Scarpa et al., Nature 2017; 543:65 Alternative Lengthening of Telomeres in pnet Loss of DAXX or ATRX results in telomerase-independent elongation of telomeres, conferring cellular immortality. Heaphy et al., Science
9 Chromosomal instability in pancreatic NETs Yao et al, J Clin Oncol 34, 2016 (suppl; abstr e23284) Summary Pancreatic NETs arise from endocrine islet cells. NET grade, stage, and primary site all contribute to clinical course and treatment options. Pancreatic NETs can cause dramatic syndromes of hormone hypersecretion. But they usually do not. New data are accumulating regarding the mutations that tend to be present in pancreatic NETs. Most pancreatic NETs are not part of a familial/inherited syndrome. 9
10 Management Management Principles Removal of localized and limited metastatic disease Advanced disease Control of hormone secretion Control of tumor growth Minimize toxicity 10
11 Cut when you can (should?) Surgical series suggest overall survival is better in patients undergoing surgery. Surgery appears to have survival advantage over observation or HAE. However, while almost anything can be cut out, the question is frequently whether it should. Bacchetti et al., Int J Hepatol 2013: Does everyone need active therapy?
12 Lanreotide in GEP-NET CLARINET Lanreotide: a somatostatin analogue binding SSTRs 2,5. Patients with SSA-avid GEP-NETs, Ki67 < 10%. Lanreotide vs. placebo. D- phe cys phe D- phe cys tyr S D- trp S D- trp S lys S lys Octreotide cys thr throl thr- NH 2 cys val Lanreotide Caplin et al., N Engl J Med 2014;371:224 Lanreotide toxicities Characteristic toxicities: Diarrhea (steatorrhea) Flatulence Cholelithiasis Hyperglycemia 12
13 Streptozocin in pnet Streptozocin: islet-specific alkylator. Initially tested in 4 pnet and 4 carcinoid patients at NCI. 1 CR for 1 year in pnet patient. 3 subsequent prospective randomized studies confirmed efficacy. However, radiographic response rates with doublets were < 10 %. The triplet of FAS has been reported to yield a response rate of 40%. Characteristic toxicities include neutropenia, hair loss, nausea/vomiting, possible cardiac toxicity mos 2.2 vs 1.5 yrs p<0.004 Moertel et al., N Engl J Med 1980; 303:1189 Moertel et al., N Engl J Med 1992; 326:519 Temozolomide Widely used but off-label (not FDA approved for NET) Range of response rates reported, probably approaching 30-40% Prospective randomized study of temozolomide +/- capecitabine is ongoing Characteristic toxicities include unusual infections, nausea, thrombocytopenia Strosberg et al., Cancer
14 Everolimus in pnet RADIANT-3 Everolimus: PO mtor inhibitor. Patients with G1-2 advanced pnets, PD within 12 months. Everolimus vs. placebo. Yao et al., N Engl J Med 2011;364:514 Everolimus toxicities Characteristic toxicities: Stomatitis Rash (capelike) Pneumonitis Lymphopenia and infections Hyperglycemia 14
15 Sunitinib in pnet Sunitinib: PO VEGFR inhibitor Patients with G1-2 advanced pnets, PD within 12 months. Sunitinib vs. placebo. Raymond et al., N Engl J Med 2011;364:501 Sunitinib toxicities Characteristic toxicities: Diarrhea Hair color changes Hypertension PPEDE 15
16 Study Liver-directed treatment options Patients n Device used Toxicity ORR (RECIST 1.0) Kennedy et al. 148 Yttrium-90(resin) 33% (grade III), fatigue (6.5%) King et al. 58 Yttrium-90(resin) plus 5-FU Radiation gastritis (2 pts), duodenal ulcer (1 pts) 63% Median: 70m 39% Median: 36m Survival times and rates Cao et al. 58 Yttrium-90(resin) Not reported 39.2% Median: 36m plus 5-FU Memon et al. 40 Yttrium-90(glass) Fatigue (63%,), nausea/vomiting (40%), grade III, IV(bilirubin, 8%; albumin, 2%; lymphocyte, 38%) WHO: 64.0%; EASL: 71.4% Median: 34.4m Loewe et al. 23 HAE Not reported 73% Median: 69m; Gupta et al 49 HAE (42) vs TACE (27) Overall complications: TACE, 20%; bland, 12% [HRS, Sepsis, abscess] Dong & Carr 123 TACE Abdominal pain (44%), diarrhoea (30%), weight loss (22%) HAE: 25% TACE: 50% 62% Mean: 3.3y Median NET: TACE, 33.8m; HAE, 33.2m; pnet: TACE, 31.5m; HAE, 18.2m Kennedy et al., HPB 2015 The Systemic Therapy Ladder Chemotherapy (Streptozocin, Temozolomide) Response Rate Targeted therapies (Everolimus, Sunitinib) Somatostatin Analogues (Octreotide/Lanreotide) Observation Tolerability 16
17 Therapeutic Approach High Volume Consider Cytotoxic Liver-directed Therapy Unresectable pnet Indolent Observation SSA Low Volume Progressive Everolimus Sunitinib Have we moved the needle? (All grades) Metastatic/Distant Grade 1-2 NET Primary Tumor Site Appendix NA Cecum 98 Colon 14 Lung 24 Pancreas 60 Rectum 33 Small Intestine 103 Stomach 29 Median Survival (months) Yao et al., J Clin Oncol 2008; 26:3063 Dasari et al., JAMA Oncol Oct 1;3(10):
18 Investigational Strategies Chemotherapy Temozolomide +/- capecitabine (NCT ) Molecularly-targeted therapy Everolimus + ribociclib (NCT ) Cabozantinib Immunotherapy PDR001 (NCT ) Atezolizumab + bevacizumab (NCT ) Receptor-targeted therapy 177 Lu-DOTATATE 177 Lu-DOTA-JR11 (NCT ) PEN-221 (NCT ) Cabozantinib (phase II) 30 Carcinoid 30 pnet Prior everolimus and/or sunitinib Courtesy of Jennifer A. Chan, MD; GI ASCO
19 Pembrolizumab in PD-L1+ NET 25% pnet PD-L1+ Mehnert et al., ESMO 2017 PRRT in midgut NET NETTER Lu-DOTA-Octreotate (DOTATATE): a radioactive isotope conjugated to somatostatin analogue. Patients with G1-2 midgut NET, PD on octreotide LAR 30, somatostatinavid. DOTATATE vs. octreotide LAR 60mg. Toxicity profile includes myelosuppression, nausea. PFS HR [95% CI ]; P< Strosberg et al., NEJM 2017; 376:
20 Symptomatic Control pnet Syndromes and Medical Management Tumor Signs/Symptoms Medical Management Insulinoma Gastrinoma Glucagonoma VIPoma Hypoglycemia with confusion, diaphoresis, weakness Refractory PUD, diarrhea Rash (necrotizing migratory erythema), diabetes, DVT Profound secretory diarrhea, electrolyte dyscrasias Frequent small meals, dextrose, diazoxide, everolimus PPI, SSA SSA SSA Adapted with permission from Halperin, Kulke, Yao. Annu Rev Med 2015; 66:1 20
21 Octreotide Octreotide LAR is FDA approved for control of carcinoid syndrome (20mg) and VIPoma. Agonist of SSTRs 2, 5. Rubin et al., JCO 1999 Kvols et al., NEJM 1986 Liver-directed therapy for hormone reduction Mitty et al., Radiology
22 Surgical Debulking R1 or R0 resection of liver metastases +/- primary tumor and nodal metastases Wilson and Butterick. Ann Surg 1959 Osborne et al., Ann Surg Onc 2006 Investigational: PRRT 177 Lutitium conjugated to octreotate for receptor-targeted tumor irradiation. Global Health Status Diarrhea Pain Flushing 177 Lu arm average % of patients Improvement 28%** 15% Worsening 18% 26% Improvement 39%** 23% Worsening 19% 23% Improvement 41% 28% Worsening 17% 25% Improvement 42% 38% Worsening 22% 19% 60mg Oct arm average % of patients Strosberg et al., J Nucl Med May 1, 2017 vol. 58 no. supplement Khan et al., J Nuc Med
23 Grade 3 NEC is not NET Grading NENs (2017) Grade 1 < 2 mitoses/10 HPF, Ki-67 <3% mitoses/10 HPF, Ki % 3 NET Well-differentiated >20 mitoses/10 HPF, Ki-67 >20% 3 NEC Poorly-differentiated >20 mitoses/10 HPF, Ki-67 >20% Grade is dependent on appearance and rate of cellular division 23
24 Grade 3 NEN Genomics Gene SCLC (N = 593) Pancreas (N = 123) Colon (N = 92) Other GI (N = 59) TP53 90% P,C,O 18% S,C,O 59% S,P 49% S,P RB1 67% P,C,O 10% S,C,O 34% S,P 29% S,P CDKN2A 3% P,O 21% S,C 5% P,O 25% S,C MEN1 1% P 33% S,C,O 3% P 2% P CDKN2B 1% P,O 16% S,C 1% P,O 19% S,C DAXX 0% P 20% S,C,O 0% P 0% P APC 2% C 3% C 47% S,P,O 8% C KRAS 4% C 7% C 37% S,P,O 3% C CCNE1 4% O 2% O 1% O 17% S,P,C S, P, C or O : Statistically significant difference compared to S = SCLC, P = Pancreas, C = colon, O = Other GI Bergsland et al., GI ASCO 2016 Grade 3 NEC has a distinct natural history Grade 1-2 Grade 3 Yao et al., J Clin Oncol 2008; 26:
25 Cisplatin/Etoposide for Grade 3 NEC Mitry et al., Br J Cancer (1999) 81(8), Investigational Strategies Chemotherapy FOLFIRINOX (NCT ) EP vs. CAPTEM (NCT ) Immunotherapy PDR001 (NCT ) Pembrolizumab (NCT ) Avelumab (NCT ) Receptor-targeted therapy PEN-221 (NCT ) Rova-T (NCT ) 25
26 Take Home Points Pancreatic NETs are not conventional pancreas cancer (adenocarcinoma) Pancreatic NECs are not conventional pancreatic NETs. Pancreatic NETs are increasing in incidence. Patients are living longer than ever. Much progress has been made in developing new effective therapy. Current challenges include: Choosing from the standard therapy menu. Choosing from the investigational menu. Thank you for your participation. If you have questions, please contact Patient Central at PANCAN or 26
MEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationReview of Gastrointestinal Carcinoid Tumors: Latest Therapies
Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine
More informationTRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationEvaluation and Management of Neuroendocrine Tumors
Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More informationSystemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid
Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University
More information2015: Year in Review Results of Recent Trials
2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research
More informationGI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust
GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationSIRT in the Management of Metastatic Neuroendocrine Tumors
SIRT in the Management of Metastatic Neuroendocrine Tumors Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director,
More informationToward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives
Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts
More informationPancreatic Neuroendocrine Tumours
UCLH Cancer Collaborative Pancreas Update Meeting 12 th July 2017 Pancreatic Neuroendocrine Tumours Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior
More informationHot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ
Hot of the press Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Outline Diagnostic developments Histopathology Molecular Therapeutic developments Results on PRRT Telotristat in carcinoid
More informationNET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ
NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body
More informationNeuroendocrine Tumors
Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More informationNuevas alternativas en el manejo de TNE avanzados
Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,
More informationA New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy
RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationWHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer
WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers
More informationTeresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal
Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6
More informationNET del pancreas ben differenziato: la terapia oncologica. Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia
NET del pancreas ben differenziato: la terapia oncologica Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia Systemic treatment op:ons Somatosta:n analogues Interpheron
More informationCollaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors
Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationTreatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece
Treatment algorithm Neuroendocrine tumours Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Outline Presenting a meaningful algorithm Means used to develop algorithm
More informationPNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.
GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March
More informationTUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca
TUMORES NEUROENDOCRINOS Miguel Navarro. Salamanca Introduction to Neuroendocrine Tumours (NETs) NETs are relatively RARE At least 40 different entities are described arising in different organs. Different
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationOPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS
OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust
More informationSelection of Appropriate Treatment
Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationNEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS
University of Miami Jackson Memorial Hospital Role of the Surgeon in the Approach to Neuroendocrine tumors Dido Franceschi, MD Professor of Surgery University of Miami Karzinoide Siegfried Oberndorfer,
More informationJaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology
Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology OUTLINE Molecular Rationale for the use of SSAs in
More informationSystemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.
Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine
More informationPeptide Receptor Radionuclide Therapy (PRRT) of NET
Peptide Receptor Radionuclide Therapy (PRRT) of NET Dr. Tuba Kendi Associate Prof of Radiology, Mayo Clinic, Rochester, MN 2014 MFMER slide-1 Relevant Financial Relationship(s) None Off Label Usage None
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationPancreatic NeuroEndocrine Tumors. Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium
Pancreatic NeuroEndocrine Tumors Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Epidemiology Overall incidence 1.8 to 2.6 SEER, Europe Peak in 5 th and 6 th decade Incidence
More informationGEP NET: algoritmo terapeutico. Dottor Nicola Fazio
GEP NET: algoritmo terapeutico Dottor Nicola Fazio Basi per il trattamento Caratteristiche del paziente Caratteristiche del tumore P.S., sindrome, comorbidità Differenziazione, Ki-67 Imaging morfologico
More informationDevelopment of New Treatment Modalities Oncolytic Viruses and Nanotechnique
Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique By Professor Kjell Öberg, M.D., Ph.D. Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden Nashville Oct. 2011 Hallmarks
More informationOngoing and future clinical investigation in GEP NENs
ESMO PRECEPTORSHIP PROGRAMME Multidisciplinary management, standards of care and future perspectives Lugano, Switzerland 13-14 April 2018 CHAIR: Nicola Fazio, Italy George Pentheroudakis, Greece Ongoing
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationNICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationOberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)
GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different
More informationSandostatin LAR. Sandostatin LAR (octreotide acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description
More informationStrategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova
Strategies in the Management of Neuroendocrine Tumors Dr. Jean Maroun Dr. Elena Tsvetkova 1 A ZORSE 2 Neuroendocrine Tumour Classification Neuroendocrine Tumours Carcinoid Tumours Pancreatic Neuroendocrine
More informationManagement of Neuroendocrine Tumors
Management of Neuroendocrine Tumors Professor Barbro Eriksson Department of Endocrine Oncology ENETS Centre of Excellence Uppsala University Hospital Diagnostic Challenges in NET Heterogeneous group of
More informationGastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic Neuroendocrine Tumors Mauro Cives, MD 1 and Jonathan R. Strosberg, MD 2 1 Assistant Professor, University of Bari, Department of Biomedical Sciences and Human Oncology, Bari, Italy;
More informationNET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες
NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1. Therapies for non-men1 pancreatic neuroendocrine tumours (NETs) (published after 2011) Somatostatin analogues Tumour type a Intervention Number of participants/information available
More informationHepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization
Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization JP King PGY2 May 22, 2015 Neuroendocrine Tumor (NET) WHO Classification Location
More informationNeuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy
Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy Lawrence Saperstein, M.D. Assistant Professor of Radiology and Biomedical Imaging Chief, Nuclear
More informationSurgical Therapy of GEP-NET: An Overview
Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior
More informationUpdate on Surgical Management of NETs
Update on Surgical Management of Neuroendocrine Tumors James R. Howe, M.D. Director, Surgical Oncology and Endocrine Surgery University of Iowa College of Medicine Distribution of NETs 2000-2004 27% ---
More informationNEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Cynthia Card (Staff Medical Oncologist, University of Calgary)
More informationEvaluation of Suspected Pancreatic Cancer
Evaluation of Suspected Pancreatic Cancer October 15, 2015 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-779-3239 Toll
More informationUpdate on pancreatic neuroendocrine tumors
Review Article Update on pancreatic neuroendocrine tumors Logan R. McKenna, Barish H. Edil Department of Surgery, University of Colorado, Academic Office One, Aurora, CO, USA Correspondence to: Barish
More informationOctreotide LAR in neuroendocrine tumours a summary of the experience
Endocrinology in oncology Review article Octreotide LAR in neuroendocrine tumours a summary of the experience Agnieszka Kolasińska-Ćwikła, MD, PhD Department of Chemotherapy, Oncology Clinic, Maria Sklodowska-Curie
More informationPANCREATIC NEUROENDOCRINE TUMOURS A
PANCREATIC NEUROENDOCRINE TUMOURS A RARE PANCREATIC TUMOUR David L Chan 1,2, Nick Pavlakis 1, Paul Roach 2, Dale Bailey 2, Jennifer Arena 3, Eva Segelov 4 1. Department of Medical Oncology, Royal North
More informationNeuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC
Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Case Study 43 yr old female with a history of a left mastectomy
More informationQOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
More informationSurgery for NET Challenges and specific aspects
Surgery for NET Challenges and specific aspects Raymond Aerts, MD Department of Abdominal Surgery and Liver Transplantation University Clinics Leuven ESMO Preceptorship on GI neuroendocrine tumours (NETs)
More informationThe PET-NET Study 2016 CNETS Grant Award
The PET-NET Study 2016 CNETS Grant Award CANM Meeting April 21, 2017 Hagen Kennecke, MD, MHA, FRCPC Medical Oncology, BC Cancer Agency Associate Professor, University of British Columbia Raja Ampat, Indonesia
More informationReview Article Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
Hindawi International Journal of Surgical Oncology Volume 2017, Article ID 6424812, 14 pages https://doi.org/10.1155/2017/6424812 Review Article Management Options for Advanced Low or Intermediate Grade
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Everolimus (Afinitor ) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin DSD: Horizon Scanning in Oncology Nr. 024 ISSN online 2076-5940
More informationUnusual Pancreatic Neoplasms RTC 2/11/2011
Unusual Pancreatic Neoplasms RTC 2/11/2011 Objectives Intraductal Papillary Mucinous Neoplasm (IPMN) Mucinous Cystic Neoplasm (MCN) Islet Cell Tumors Insulinoma Glucagonoma VIPoma Somatostatinoma Gastrinoma
More informationIART Cremona,
IART Cremona, 06-06-2018 Quale spazio per la terapia biologica? Nicola Fazio, M.D., Ph. D. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors European Institute of Oncology Milan, Italy
More informationNew Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer
New Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer Centre MD, FRCPC CAGPO September 2018 Disclosures Consultant
More informationAddison's disease Neuroendocrine tumors Paraneoplastic syndromes
Addison's disease Neuroendocrine tumors Paraneoplastic syndromes Miklós Tóth Professor of Medicine and Endocrinology 9 th April, 2018 Semmelweis University 2nd Department of Medicine Addison's disease
More informationUpdates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010
HIGHLIGHT ARTICLE Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010 Susan Alsamarai 1, Steven K Libutti 2, Muhammad Wasif Saif
More informationWhat the oncologist needs to know from the pathologist?
Grade 3 GEP Neuroendocrine Neoplasms: from pathology to the clinic and back What the oncologist needs to know from the pathologist? Marianne Pavel Friedrich Alexander Universität Erlangen-Nürnberg 30th
More informationNEUROENDOCRINE TUMORS
NEUROENDOCRINE TUMORS A PRIMER FOR HEALTHCARE PROFESSIONALS Advocating the Right Team, the Right Treatment, at the Right Time for Neuroendocrine (NET) patients and physicians educating I funding I supporting
More informationSystemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update
Focused Review 777 Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update Diane L. Reidy-Lagunes, MD, MS Abstract Well-differentiated neuroendocrine tumors (NETs) can be subdivided into
More informationNeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction
NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Diagnostic & therapeutic
More informationMEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)
MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including an Essential
More informationNeuro-endocrine and pancreatic non-adenocarcinomas. Marc Engelbrecht, AMC, Amsterdam
Neuro-endocrine and pancreatic non-adenocarcinomas Marc Engelbrecht, AMC, Amsterdam Pancreatic Tumors q Epithelial Exocrine q Mesenchymal Ductal Adenocarcinoma (85-95%) Metastasis Lymfoma Acinar Cell Carcinoma
More informationSystematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors
At the Cutting Edge Received: February 29, 2016 Accepted: April 12, 2016 Published online: April 16, 2016 Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors Adrian Lee
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationManagement of Pancreatic Islet Cell Tumors
Management of Pancreatic Islet Cell Tumors Ravi Dhanisetty, MD November 5, 2009 Morbidity and Mortality Conference Case Presentation 42 yr female with chronic abdominal pain. PMHx: Uterine fibroids Medications:
More informationPancreatic Neuroendocrine Tumors: Entering a New Era Highlights from the 2012 ASCO Gastrointestinal Cancers Symposium.
HIGHLIGHT ARTICLE Pancreatic Neuroendocrine Tumors: Entering a New Era Highlights from the 2012 ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA. January 19-21, 2012 Paul E Oberstein 1,
More informationDiagnosing and monitoring NET
Diagnosing and monitoring NET Inaccurate or delayed diagnosis of neuroendocrine tumors (NET) is common, because many NET are small and asymptomatic. 1 When symptoms are present, they are usually nonspecific
More informationImaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear
Imaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear Eric Tamm, M.D. Department of Diagnostic Radiology Division of Diagnostic Imaging MD Anderson Cancer Center Houston, TX Disclosure
More informationAn Immunotherapy Clinical Trial for NETs
An Immunotherapy Clinical Trial for NETs Pamela L. Kunz, MD Assistant Professor of Medicine / Oncology Stanford Cancer InsEtute March 1, 2015 Outline Clinical trial basics What have we learned from recent
More informationAn Overview of NETS. Richard R.P. Warner M.D
An Overview of NETS Richard R.P. Warner M.D Diagnosis and Treatment Approaches Carcinoid (and other NETs) not as benign as originally described 13-50% of all carcinoids have distant metastases when first
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Sunitinib malate (Sutent) for pancreatic neuroendocrine tumours May 3, 2012
pan-canadian Oncology Drug Review Final Clinical Guidance Report Sunitinib malate (Sutent) for pancreatic neuroendocrine tumours May 3, 2012 DISCLAIMER Not a Substitute for Professional Advice This report
More informationFRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS)
FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) Gilda s Club Quad Cities November 5 th, 2018 Joseph Dillon, MD Neuroendocrine Tumor Clinic University of Iowa Hospitals & Clinics
More informationSOMATULINE DEPOT (lanreotide acetate)
SOMATULINE DEPOT (lanreotide acetate) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationRare GI Malignancies
Rare GI Malignancies Jordan Karlitz, MD Associate Professor of Medicine, Division of Gastroenterology Director, Hereditary GI Cancer and Genetics Program Tulane University School of Medicine Outline Gastrointestinal
More informationGEP NEN. Personalised approach. Curative and Palliative Surgery. ESMO Preceptorship Programme Neuroendocrine Neoplasms Lugano April 2018
GEP NEN Personalised approach Curative and Palliative Surgery ESMO Preceptorship Programme Neuroendocrine Neoplasms Lugano 13 14 April 2018 Professor Andrea Frilling Department of Surgery and Cancer Imperial
More informationSURGERY OF NETS. Iakovos N Nomikos MD FACS. Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece
SURGERY OF NETS Iakovos N Nomikos MD FACS Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece Epidemiology 5-fold increase in occurrence of NETS over past 30 years
More informationPancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case
Case Report Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case Yang Wang, Dongbing Zhao Department of Abdominal Surgery, Cancer Institute & Hospital,
More informationTHERAPEUTIC RADIOPHARMACEUTICALS
UnitedHealthcare of California (HMO) UnitedHealthcare Benefits Plan of California (EPO/POS) UnitedHealthcare of Oklahoma, Inc. UnitedHealthcare of Oregon, Inc. UnitedHealthcare Benefits of Texas, Inc.
More informationPharmacy Prior Authorization Somatostatin Analogs Clinical Guideline
Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce
More informationCRITICAL ANALYSIS OF NEN GUIDELINES. G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines
CRITICAL ANALYSIS OF NEN GUIDELINES G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines DISCLOSURES NO CONFLICTS OF INTEREST TO DECLARE UPDATED
More informationAn Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT )
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) J.M. Xu a, J. Li b, C.M. Bai c, N. Xu d, Z.W. Zhou e, Z.P. Li f, C.C. Zhou g, W. Wang h, J. Li
More information